We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
McKesson (MCK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Read MoreHide Full Article
McKesson (MCK - Free Report) closed the most recent trading day at $853.81, moving -1.27% from the previous trading session. This change lagged the S&P 500's daily loss of 0.25%. On the other hand, the Dow registered a loss of 0.86%, and the technology-centric Nasdaq increased by 0.24%.
Heading into today, shares of the prescription drug distributor had lost 4.63% over the past month, lagging the Medical sector's loss of 1.01% and the S&P 500's loss of 0.42%.
The investment community will be closely monitoring the performance of McKesson in its forthcoming earnings report. The company is scheduled to release its earnings on November 4, 2026. On that day, McKesson is projected to report earnings of $10.72 per share, which would represent year-over-year growth of 8.72%. Alongside, our most recent consensus estimate is anticipating revenue of $110.14 billion, indicating a 6.78% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $44.64 per share and revenue of $429.09 billion, which would represent changes of +14.14% and +6.36%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for McKesson. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% lower. Right now, McKesson possesses a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that McKesson has a Forward P/E ratio of 19.37 right now. This indicates a premium in contrast to its industry's Forward P/E of 17.02.
It's also important to note that MCK currently trades at a PEG ratio of 1.72. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Dental Supplies industry currently had an average PEG ratio of 1.94 as of yesterday's close.
The Medical - Dental Supplies industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 107, placing it within the top 44% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
McKesson (MCK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
McKesson (MCK - Free Report) closed the most recent trading day at $853.81, moving -1.27% from the previous trading session. This change lagged the S&P 500's daily loss of 0.25%. On the other hand, the Dow registered a loss of 0.86%, and the technology-centric Nasdaq increased by 0.24%.
Heading into today, shares of the prescription drug distributor had lost 4.63% over the past month, lagging the Medical sector's loss of 1.01% and the S&P 500's loss of 0.42%.
The investment community will be closely monitoring the performance of McKesson in its forthcoming earnings report. The company is scheduled to release its earnings on November 4, 2026. On that day, McKesson is projected to report earnings of $10.72 per share, which would represent year-over-year growth of 8.72%. Alongside, our most recent consensus estimate is anticipating revenue of $110.14 billion, indicating a 6.78% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $44.64 per share and revenue of $429.09 billion, which would represent changes of +14.14% and +6.36%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for McKesson. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% lower. Right now, McKesson possesses a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that McKesson has a Forward P/E ratio of 19.37 right now. This indicates a premium in contrast to its industry's Forward P/E of 17.02.
It's also important to note that MCK currently trades at a PEG ratio of 1.72. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Dental Supplies industry currently had an average PEG ratio of 1.94 as of yesterday's close.
The Medical - Dental Supplies industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 107, placing it within the top 44% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.